Cargando…

非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析

OBJECTIVE: To explore the clinical characteristics and prognostic factors of the patients with non-Hodgkin's Lymphoma (NHL) complicated with HBV infection, so as to provide a basis for clinical accurate diagnosis and prognosis evaluation. METHODS: The data of 313 newly diagnosed NHL patients fr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342218/
https://www.ncbi.nlm.nih.gov/pubmed/30122015
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.007
_version_ 1783555408506388480
collection PubMed
description OBJECTIVE: To explore the clinical characteristics and prognostic factors of the patients with non-Hodgkin's Lymphoma (NHL) complicated with HBV infection, so as to provide a basis for clinical accurate diagnosis and prognosis evaluation. METHODS: The data of 313 newly diagnosed NHL patients from August 2012 to July 2016 were collected. The HBV serological markers were detected by ELISA, and HBV DNA was quantified by full automatic microparticle chemiluminescence immunoassay (≥1×10(5) copies/ml as high copy group, 1×10(3)–<1×10(5) copies/ml as low copy group). The relationship between HBV infection and prognosis was analyzed combined with the clinical features of the patients, and the HBV detection rate was compared with that of the common population (from the national HBV sero epidemiological data). RESULTS: ①The positive rate of HBsAg in NHL patients was 12.5% (39/313), which was higher than 7.2% in the general population (χ(2)=14.596, P<0.001). HBV infection in the past (HBsAg negative but HBcAb positive) in 114 cases (36.4%), the incidence was slightly higher than that in the general population (34.1%). ②Compared HBsAg positive group with the negative group, the proportion of B cell type (87.2% vs 70.3%, P=0.027), Ann Arbor stage Ⅲ–Ⅳ(69.2% vs 34.6%, P<0.001), IPI score 3–5 (74.4% vs 50%, P=0.004), LDH level (79.5% vs 47.8%, P<0.001) and liver involvement (45.5% vs 31.7%, P=0.006) were all higher. The difference was statistically significant. ③Compared the HBV infected group (114 cases) with the non-infected group (160 cases), the difference had statistical significance in the proportion of Ann Arbor stage Ⅲ–Ⅳ (P=0.023) and IPI score 3–5 scores P=0.035). ④Compared HBV DNA positive group (30 cases) with negative group (71 cases), Ann Arbor stage Ⅲ–Ⅳ (P=0.011), IPI score 3–5 score (P=0.030), LDH level (P=0.025) and liver involvement (P<0.001) in the proportion of patients had statistical significance. The positive patients were divided into HBV DNA high and low copy groups with 1×10(5) copies of /ml as the boundary. The results showed that there was no statistical difference between the two groups (P>0.05). CONCLUSION: The HBV infection rate of NHL patients is significantly higher than that of the general population, and HBV infection is more closely related to B cell type NHL. Patients with HBV infection and HBV DNA positive had late Ann Arbor stage, high IPI score, high LDH level and liver involvement, and the prognosis is poor.
format Online
Article
Text
id pubmed-7342218
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422182020-07-16 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the clinical characteristics and prognostic factors of the patients with non-Hodgkin's Lymphoma (NHL) complicated with HBV infection, so as to provide a basis for clinical accurate diagnosis and prognosis evaluation. METHODS: The data of 313 newly diagnosed NHL patients from August 2012 to July 2016 were collected. The HBV serological markers were detected by ELISA, and HBV DNA was quantified by full automatic microparticle chemiluminescence immunoassay (≥1×10(5) copies/ml as high copy group, 1×10(3)–<1×10(5) copies/ml as low copy group). The relationship between HBV infection and prognosis was analyzed combined with the clinical features of the patients, and the HBV detection rate was compared with that of the common population (from the national HBV sero epidemiological data). RESULTS: ①The positive rate of HBsAg in NHL patients was 12.5% (39/313), which was higher than 7.2% in the general population (χ(2)=14.596, P<0.001). HBV infection in the past (HBsAg negative but HBcAb positive) in 114 cases (36.4%), the incidence was slightly higher than that in the general population (34.1%). ②Compared HBsAg positive group with the negative group, the proportion of B cell type (87.2% vs 70.3%, P=0.027), Ann Arbor stage Ⅲ–Ⅳ(69.2% vs 34.6%, P<0.001), IPI score 3–5 (74.4% vs 50%, P=0.004), LDH level (79.5% vs 47.8%, P<0.001) and liver involvement (45.5% vs 31.7%, P=0.006) were all higher. The difference was statistically significant. ③Compared the HBV infected group (114 cases) with the non-infected group (160 cases), the difference had statistical significance in the proportion of Ann Arbor stage Ⅲ–Ⅳ (P=0.023) and IPI score 3–5 scores P=0.035). ④Compared HBV DNA positive group (30 cases) with negative group (71 cases), Ann Arbor stage Ⅲ–Ⅳ (P=0.011), IPI score 3–5 score (P=0.030), LDH level (P=0.025) and liver involvement (P<0.001) in the proportion of patients had statistical significance. The positive patients were divided into HBV DNA high and low copy groups with 1×10(5) copies of /ml as the boundary. The results showed that there was no statistical difference between the two groups (P>0.05). CONCLUSION: The HBV infection rate of NHL patients is significantly higher than that of the general population, and HBV infection is more closely related to B cell type NHL. Patients with HBV infection and HBV DNA positive had late Ann Arbor stage, high IPI score, high LDH level and liver involvement, and the prognosis is poor. Editorial office of Chinese Journal of Hematology 2018-07 /pmc/articles/PMC7342218/ /pubmed/30122015 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.007 Text en 2018年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title_full 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title_fullStr 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title_full_unstemmed 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title_short 非霍奇金淋巴瘤合并HBV感染患者的临床特征及预后相关因素分析
title_sort 非霍奇金淋巴瘤合并hbv感染患者的临床特征及预后相关因素分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342218/
https://www.ncbi.nlm.nih.gov/pubmed/30122015
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.07.007
work_keys_str_mv AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī
AT fēihuòqíjīnlínbāliúhébìnghbvgǎnrǎnhuànzhědelínchuángtèzhēngjíyùhòuxiāngguānyīnsùfēnxī